Lassa Fever Treatment Market - Top Companies and Manufacturers

In the News

• INOVIO, a biotechnology company focused on the development and commercialization of DNA medicines for the treatment and prevention of infectious diseases, cancer, and HPV-related diseases, today announced a collaboration with its partner Epidemic Preparedness Innovations Coalition to develop DNA medicines announced that they had signed an agreement to cancel the event. Following initial analysis of data from a study conducted by INOVIO and funded by CEPI, a product candidate for Lassa fever and Middle East respiratory syndrome has been announced.
• IAVI, a nonprofit scientific research organization, is conducting a Phase I clinical trial, called IAVI C102, using a novel Lassa fever virus vaccine with support from IAVI, in which volunteers from the PREVAIL clinical trial facility at Redemption Hospital in Monrovia, Liberia announced that they are participating in. Candidates from the Coalition for Infectious Disease Prevention Innovations received vaccinations. This study, sponsored by IAVI, is part of an existing partnership with CEPI that began in 2018 and is a global consortium of IAVI and partners to advance the development of IAVI's LASV vaccine candidate through clinical trial support Phases I and II. Provides up to USD 61.7 million to support.